Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q4 2024 Earnings Presentation
16 slides from Bionano Genomics's earnings presentation, Mar 31, 2025
Slide 1: Q4 & FY24 Financial Results Webcast & Call
Q4& FY24 Financial Results Webcast & Call March 31st 2025
Slide 2: Safe harbor statement
Safe harbor statement - This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan," anticipate,” “estimate,” “intend,” “should,” “believe,” “would,” “could,” “potential,” “outlook,” “
Slide 3: Q4 2024 Results
Q4 2024 Results 371 400 363 368 9.0 347 8.7 326 350 • Q4 Revenues: $8.2M 301 8.2 (-24% vs. Q4’23) 281 300 7.0 7.2 7.3 259 7.1 7.1 6.7 240 6.6 250 • GAAP Gross margin of 42%; OGM Installed Base 6.1 5.9 217 non-GAAP gross margin of 42% Revenue 5.0 5.2 5.3196 176 200 141 164 4.6 • GAAP OpEx $15.4M; 3.0
Slide 4: 2024 Full Year Results
2024 Full Year Results $30.8 M $12.8 M +9% 2024 Revenues 2024 Consumables AMR Core Revenue (vs $36.1 M in 2023) Revenues Growth vs 2023 (vs $11.2 in 2023) $29.1 M $6.2 M +10% 2024 Core Revenues Software Revenue EMEA Core Revenue (vs $29.0 in 2023) (vs $5.6 M in 2023) Growth vs 2023 $27.0 M 30,307 -4
Slide 5: Strategic Update
Strategic Update 5
Slide 6: OGM a superior alternative to conventional cytogenetics
We believe OGM on Saphyr® & Stratys systems is a superior alternative to conventional cytogenetics in four significant areas of clinical research Heme malignancies Constitutional genetic disorders • Blood cancers such as: Publication: • Genetic conditions such as developmental Publication: Leukemias
Slide 7: Strategic Pillars and Key Imperatives for 2025
Strategic Pillars and Key Imperatives for 2025 Drive utilization through Support & sustain the adoption of VIA software installed base of routine OGM across routine OGM users & & VIA software users facilitate menu expansion Improve profitability and Build support needed for scalability with lower co
Slide 8: Flowcells Purchased
Strong flowcell purchases in ‘24 despite adding fewer systems; Routine use sites are the ones driving growth & our focus Routine Use Sites 7,000 (118 as of 12/31/24 in US, CA, EU, UK & Israel) 6,000 Flowcells Purchased Flowcells Purchased 5,000 4,000 All Other Sites 3,000 (excl APAC) 2,000 1,000 0 Q
Slide 9: VIA software used by non-OGM sites and OGM sites
Our VIA software is used by non-OGM sites for analysis of NGS & microarray data and by OGM sites for analysis of all three 133 Non-OGM VIA Customers 56,000 Non-OGM Samples Processed on VIA in 2024 161 OGM Customers with VIA installed (as of 12/31/24 up from 40 12/31/23) © Copyright 2025 Bionano Geno
Slide 10: Publications and cumulative clinical research genomes
We believe the growth in publications and clinical research genomes published are important for building support for widespread use of OGM +82 Publications in Q4 2024 for total Over ~8,100 published human clinical publications at YE’24 of 336, a 19% research genomes increase vs 2023 336 350 8,000 On
Slide 11: Category I CPT code for OGM effective January 1, 2025
Category I CPT code for OGM in hematological malignancy analysis effective on CLFS January 1, 2025 • New Category I Current Procedural Terminology (CPT) code for the use of American Medical Association (AMA) CPT Code for OGM OGM in cytogenomic genome-wide analysis to detect structural and copy numbe
Slide 12: Important steps to help us deliver against our vision
Important steps to help us deliver against our vision Gross Margin Improvement Non-GAAP Gross Margin ✓ Gross Margin for the core business (non- 45% Core Revenues GAAP) has improved over the previous 8 Qtrs 35% from 22% in Q1 2023 to 42% in Q4 2024 25% Projected Cost Savings ✓ Over $100M projected cu
Slide 13: Financial Overview
Financial Overview bionano 13
Slide 14: Streamlined Business Focus and 2025 Guidance
Bionano is focused on driving existing customer sites that are expanding capacity and in key target geographies Streamlined Business Focus 2025 Guidance • Support & sustain the installed OGM FY’25 Total Revenue Guidance: base of routine OGM & VIA software users $29 – $32M • Drive utilization through
Slide 15: Questions & Answers
Questions & Answers bionano 5)
Slide 16: Thank you.
= Thank you.